Skip to main content

EL RECEPTOR NUCLEAR NOR-1 EN EL REMODELADO CARDIACO Y VASCULAR: ANALISIS DE MECANISMOS FISIOPATOLOGICOS Y VALIDACION DE NUEVOS MODELOS ANIMALES DE UTILIDAD PRECLINICA

SAF2015-64767-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lysyl oxidase overexpression accelerates cardiac remodeling and aggravates angiotensin II-induced hypertrophy

  • Galán Arroyo, María
  • Varona, Saray
  • Guadall, Anna
  • Orriols, Mar
  • Navas, Miguel
  • Aguiló, Silvia
  • Diego, Alicia de
  • Navarro, María A.
  • García-Dorado, David
  • Rodríguez-Sinovas, Antonio
  • Martínez-González, José
  • Rodríguez-Sinovas, Cristina
Lysyl oxidase (LOX) controls matrix remodeling, a key process that underlies cardiovascular diseases and heart failure; however, a lack of suitable animal models has limited our knowledge with regard to the contribution of LOX to cardiac dysfunction. Here, we assessed the impact of LOX overexpression on ventricular function and cardiac hypertrophy in a transgenic LOX (TgLOX) mouse model with a strong cardiac expression of human LOX. TgLOX mice exhibited high expression of the transgene in cardiomyocytes and cardiofibroblasts, which are associated with enhanced LOX activity and H2O2 production and with cardiofibroblast reprogramming. LOX overexpression promoted an ageassociated concentric remodeling of the left ventricle and impaired diastolic function. Furthermore, LOX transgenesis aggravated angiotensin II (Ang II)–induced cardiac hypertrophy and dysfunction, which triggered a greater fibrotic response that was characterized by stronger collagen deposition and cross-linking and high expression of fibrotic markers. In addition, LOX transgenesis increased the Ang II–induced myocardial inflammatory infiltrate, exacerbated expression of proinflammatory markers, and decreased that of cardioprotective factors. Mechanistically, LOX overexpression enhanced oxidative stress and potentiated the Ang II–mediated cardiac activation of p38 MAPK while reducing AMPK activation. Our findings suggest that LOX induces an age-dependent disturbance of diastolic function and aggravates Ang II–induced hypertrophy, which provides novel insights into the role of LOX in cardiac performance, This work was cofunded by the Spanish Ministerio de Econom´ıa y Competitividad (MINECO)–Instituto de Salud Carlos III (ISCIII) (Grants PI15/01016, SAF2015-64767-R, RD12/0042/0021 and RD12/0042/0053), Fundacio La ´ Marato de TV3 (20152330 and 20153610), and the Fondo ´ Europeo de Desarrollo Regional, a way to build Europe. Centros de Investigacion Biom ´ edica en Red de Enfermedades ´ Cardiovasculares is an initiative of ISCIII. M.G. was supported by the Miguel Servet Program (ISCIII; CP15/00126)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Endothelial NOD1 directs myeloid cell recruitment in atherosclerosis through VCAM-1

  • González-Ramos, Silvia
  • Paz-García, Marta
  • Rius, Cristina
  • Monte-Monge, Alberto del
  • Rodríguez-Sinovas, Cristina
  • Fernández-García, Victoria
  • Andrés, Vicente
  • Martínez-González, José
  • Lasunción, Miguel A.
  • Martín-Sanz, Paloma
  • Soehnlein, Oliver
  • Boscá, Lisardo
Atherosclerosis is a chronic disease characterized by vascular lipid retention and inflammation, and pattern recognition receptors (PRRs) are important contributors in early stages of the disease. Given the implication of the intracellular PRR nucleotide-binding oligomerization domain 1 (NOD1) in cardiovascular diseases, we investigated its contribution to early atherosclerosis. We evidenced NOD1 induction in atherosclerotic human and mouse tissues, predominantly in vascular endothelial cells. Accordingly, NOD1 genetic inactivation in Apoe-/- mice reduced not only atherosclerosis burden, but also monocyte and neutrophil accumulation in atheromata. Of note, in the presence of either peptidoglycan or oxidized LDLs, endothelial NOD1 triggered VCAM-1 up-regulation through the RIP2-NF-¿B axis in an autocrine manner, enhancing firm adhesion of both sets of myeloid cells to the inflamed micro- and macrovasculature in vivo. Our data define a major proatherogenic role for endothelial NOD1 in early leukocyte recruitment to the athero-prone vasculature, thus introducing NOD1 as an innovative therapeutic target and potential prognostic molecule, This work was supported bythe the Ministry of Science, Innovation and Universities(Grants SAF2015-64767-R, SAF2016-79490-R, SAF2015-70747-R, SAF2016-75004-R, SAF2017-82436-R/RTC2017-6283-1), the Center for Biomedical Research Network Consortium in Cardiovascular Diseases (Grants CB16/11/00257, CB16/11/00405, CB/11/00222), Community of Madrid Grant BMD/3686, the German Research Foundation (Grants SFB914 TPA02/B08/B09/Z03, SFB1123 TP A06/B05/B08/Z01), and the Netherlands Organization for Scientific Research (VIDI proj-ect 91712303). This project was also financed, in part, by theEuropean Regional Development Fund. O.S. and L.B. con-tributed equally as senior authors.